MX2020006105A - Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. - Google Patents

Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.

Info

Publication number
MX2020006105A
MX2020006105A MX2020006105A MX2020006105A MX2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
atopic dermatitis
formulations
peptide immunogen
Prior art date
Application number
MX2020006105A
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2020006105A publication Critical patent/MX2020006105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente descripción está dirigida a construcciones de inmunógenos peptídicos individuales dirigidas a porciones de la proteína Interleucina-31 (IL-31) para el tratamiento y/o la prevención de una afección pruriginosa y/o afección alérgica, como la dermatitis atópica. La presente descripción también se dirige a composiciones que contienen las construcciones de inmunógenos peptídicos, métodos de fabricación y uso de las construcciones de inmunógenos peptídicos y anticuerpos producidos por las construcciones de inmunógenos peptídicos.
MX2020006105A 2017-12-11 2018-12-11 Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. MX2020006105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597130P 2017-12-11 2017-12-11
PCT/US2018/065025 WO2019118512A2 (en) 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2020006105A true MX2020006105A (es) 2020-11-09

Family

ID=66820956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006105A MX2020006105A (es) 2017-12-11 2018-12-11 Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.

Country Status (12)

Country Link
US (1) US20210079054A1 (es)
EP (1) EP3724218A2 (es)
JP (1) JP7250032B2 (es)
KR (1) KR102745247B1 (es)
CN (1) CN111448208B (es)
AU (1) AU2018383708B2 (es)
BR (1) BR112020011308A2 (es)
CA (1) CA3085318A1 (es)
MX (1) MX2020006105A (es)
SG (1) SG11202005526WA (es)
TW (1) TWI741241B (es)
WO (1) WO2019118512A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2019178601A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Peptide vaccines against interleukin-31
US20220324960A1 (en) * 2019-08-29 2022-10-13 Kindred Biosciences, Inc. Anti-IL31 Antibodies for Veterinary Use
MX2022009320A (es) * 2020-01-28 2022-09-19 United Biomedical Inc Inmunógenos péptidos dirigidos a pcsk9 y formulaciones de los mismos para la prevención y el tratamiento de trastornos mediados por pcsk9.
WO2022109403A1 (en) * 2020-11-23 2022-05-27 Scout Bio, Inc. Antigen-binding molecules and uses thereof
JP2024504194A (ja) * 2021-01-29 2024-01-30 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
US20180267024A1 (en) * 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
BR112018003967A2 (en) * 2015-09-08 2018-09-25 Universität Zürich Insect bite hypersensitivity treatment
AU2017256727B2 (en) * 2016-04-27 2022-09-29 Saiba Animal Health Ag Treatment of canine atopic dermatitis

Also Published As

Publication number Publication date
JP2021510169A (ja) 2021-04-15
CN111448208A (zh) 2020-07-24
WO2019118512A3 (en) 2020-04-09
SG11202005526WA (en) 2020-07-29
RU2020122924A (ru) 2022-01-14
KR20210009296A (ko) 2021-01-26
TWI741241B (zh) 2021-10-01
CN111448208B (zh) 2024-02-27
US20210079054A1 (en) 2021-03-18
AU2018383708B2 (en) 2023-10-26
EP3724218A2 (en) 2020-10-21
JP7250032B2 (ja) 2023-03-31
TW201927813A (zh) 2019-07-16
CA3085318A1 (en) 2019-06-20
BR112020011308A2 (pt) 2020-11-17
WO2019118512A2 (en) 2019-06-20
AU2018383708A1 (en) 2020-07-16
KR102745247B1 (ko) 2024-12-23

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2021003036A2 (es) Compuestos de anillo fusionado
PY1800237A (es) Aislados de bacillus y usos de los mismos
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2023014569A (es) Anticuerpos anti-sirpa.
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
UY38476A (es) Inhibidores de arg1 y/o arg2
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
EA202092202A1 (ru) Конструкции антител к ror
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
UY37635A (es) Anticuerpos anti phf-tau y sus usos
UY35474A (es) Métodos y composiciones para el control de malezas y molécula de polinucleótidos útil en dicho método.
GT201700188A (es) Anticuerpos contra tau y sus usos
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
WO2019118512A3 (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CR20180529A (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
CO2022014150A2 (es) Anticuerpos anti-interleucina-33 y usos de estos
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.